2012 Awards

ACP Mcelwain Prize

Oral presentation:

The preclinical and clinical development of AKT inhibitors and associated biomarkers
Timothy Yap, Royal Marsden Hospital and The Institute of Cancer Research, London, UK

Poster presentation:

Economic evaluation of genomic test-directed chemotherapy for women with lymph node-positive, oestrogen receptor-positive early breast cancer
Peter S. Hall, University of Leeds, UK

Astrazeneca Student Prize Award

The AstraZeneca Student Prize Award is awarded to one high-quality abstract submitted by a student. AstraZeneca is proud to support excellence in research by young scientists. The recipient receives a bursary covering registration, accommodation and travel to the NCRI Conference. The 2012 Prize was awarded to:
Identification of metabolic genes essential for proliferation of clear cell renal cell carcinoma (ccRCC) cells
Heike Miess et al., Cancer Research UK London Research Institute, UK

Metastasis driven by the tumour microenvironment
Janine T. Erler, University of Copenhagen, Denmark

Characterisation of expressed fusion genes in micropapillary carcinomas of the breast
Rachael Natrajan, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK

British Association of Cancer Research (BACR)/Gordon Hamilton-Fairleyyoung Investigator Award

The BACR/Gordon Hamilton-Fairley Young Investigator Award recognises and encourages the talents of more junior cancer researchers. The winner of the 2012 Award was:
The role of p53 in hypoxia-induced apoptosis
Katarzyna Leszczynskai et al., University of Oxford, UK

Cancer Research UK Prize Award

Lifetime Achievement in Cancer Research Prize

The Cancer Research UK Lifetime Achievement in Cancer Research Prize honours an individual who has demonstrated a lifetime commitment to the fight against cancer, making exceptional advances in the field, and who has had a significant and sustained role in furthering our understanding of cancer or a major impact on the lives of people with cancer.
David Lane, Agency for Science, Technology and Research, Singapore

Future Leaders in Cancer Research Prize

The Future Leaders in Cancer Research Prize recognises individuals who have completed their PhD within the last ten years and have demonstrated the potential to achieve world-leading status by producing international quality research.

The successful recipients of this prize will have produced international quality research, and demonstrated ambition and aspirations consistent with the potential exhibited by current world leaders at that stage of their career.
Owen Sansom, The Beatson Institute for Cancer Research, Glasgow, UK
Jason Carroll, Cancer Research UK Cambridge Research Institute, UK

Children’s Cancer and Leukaemia Group (CCLG) Mcelwain Award

The CCLG McElwain Award will be offered for the best abstract on childhood cancer research. The award is in honour of Professor Timothy McElwain, one of the pioneers of cancer chemotherapy including childhood malignancies.
The winner of the 2012 Award was:
Dissecting the clonal architecture of paediatric leukaemia
Nicola Potter , The Institute of Cancer Research, London, UK

National Cancer Research Institute (NCRI) Prize Awards

The NCRI Prize Awards give PhD students who submitted an abstract as first author a prize bursary of up to £250 towards the cost of attending the Conference. Applicants for this award were asked why they chose to attend the NCRI Cancer Conference and how they feel they will benefit by attending. The winners of the awards were selected on the basis of both the quality of their abstract and the strength of their supporting application.
Alcohol consumption, body mass index and breast cancer prognosis: results from the SEARCH study
Alaa Ali et al., University of Cambridge, UK and South Egypt Cancer Institute, Assiut, Egypt

Hydration status in advanced cancer patients: assessment of a novel evaluation technique
Amara Nwosu et al., Marie Curie Palliative Care Institute Liverpool, UK

A study on kinetochore-spindle microtubule attachment: Ndc80 and TOG/MAPs
Ngang Heok Tang et al., Cancer Research UK, London Research Institute, UK

MST2 promotes migration and invasion in head and neck cancer
Carles Escriu et al., Cancer Research UK Cambridge Research Institute and University of Cambridge, UK

LARP1: An ovarian cancer biomarker with prognostic significance
Tom G. Hopkins et al.,Imperial College London, UK

UK audit of outcomes from temsirolimus expanded access program in advanced renal cancer
Philip Earwaker et al.,University of Oxford & Oxford University Hospitals NHS Trust, UK

Synthetic lethal targeting of a homologous recombination repair defect in PTEN-deficient melanoma cell linesusing inhibitors of human apurinic/apyrimidinic endonuclease (APE1)
Rachel Abbotts et al., University of Nottingham, UK and National Institute on Aging, Baltimore, USA

Effects of individual isoforms of VEGFA on tumour response to the tyrosine kinase inhibitor cediranib
Rachel A. Daniel et al., University of Sheffield, UK

Perceptions of the English NHS Bowel Cancer Screening Programme information materials: A Think-Aloud study
Samuel G. Smith et al., University College London, UK

Yoga for gynaecological cancer patients: The patient experience
Stephanie Archer et al., University of Derby, UK

Development of a cell-based assay to study the impact of the class III phosphoinositide 3-kinase on cancer cell biology
Michalina Gruszka et al., Barts Cancer Institute, Queen Mary University London, UK

Resistance mechanisms to mTOR inhibition in renal cancer
Philip Earwaker et al., University of Oxford & Oxford University Hospitals NHS Trust, UK

A mesenchymal-epithelial transition in the prostate stroma marks the initiation of prostatic reprogramming to an embryonic stem cell state
Deepali Pal et al., Northern Institute for Cancer Research, Newcastle University, UK

Induced pluripotent stem cell (iPSC) reprogramming of the elderly human prostate into a primitive embryonic stem cell state – A model for prostatic development and carcinogenesis
Deepali Pal et al., Northern Institute for Cancer Research, Newcastle University, UK

The role of NG2/CSPG4 in resistance to radiotherapy in glioblastoma cells
Richard Heywood et al., Cambridge Centre for Brain Repair, University of Cambridge, UK

Targeting radiation resistance with the AKT clinical candidate MK-2206
Aswin George Abraham et al., Gray Institute for Radiation Oncology and Biology, University of Oxford, UK

Richard Hambro Student Prize

The Richard Hambro Prizes are awarded by Cancer Research UK and are supported by a generous donation from the Joint British Cancer Charities. Richard Hambro became involved with the Joint British Cancer Charities in the early 1980s through his step mother, the then Duchess of Roxburghe, who was President of the JBCC. Hambros Bank sponsored a Business Man of the Year lunch which raised substantial funds for the JBCC over many years. Richard Hambro was also Treasurer and subsequently Chairman of Macmillan Cancer Relief and oversaw its exceptional growth into a national charity over some twenty years.
There are two Prize categories:
1) Prizes for the best abstracts – PhD students who, in the opinion of the judging panel submitted one of the best abstracts, will be awarded a bursary of up to £250 (to cover registration, accommodation and travel costs).
2) Prizes for the best posters – all winners of the Richard Hambro Student Prize for the best abstract (who will be awarded a bursary) are required to present a poster at the NCRI Cancer Conference. These posters will be judged by the Conference Planning Committee and three students will be awarded an additional first, second or third prize for producing the best posters.

1st prize for best poster presentation & recipient of bursary for best abstract

Propagation of epithelial polarity through mitosis
Graham Bell et al., Cancer Research UK & University College London, UK

Runners up for poster presentation & recipient of bursary for best abstract

RASSF1A loss deregulates hippo pathway signalling in tumouri
Angelos Papaspyropoulos et al., University of Oxford, UK

Investigating the functional effects of oncogenic FGFR2 mutations in endometrial cancer
Abbie Fearon et al., Barts Cancer Institute, London, UK

Recipients of bursary for best abstract

Validation of a novel diagnostic standard in HPV positive oropharyngeal squamous cell carcinoma
Andrew Schache et al., University of Liverpool, UK

HELQ helicase, a novel DNA crosslink repair protein with links to the RAD51 paralog BCDX2 complex
Rafal Lolo et al., Cancer Research UK London Research Institute, UK

PIK3CA mutation is strongly associated with K-ras 12/13 mutation in stage II/III colorectal cancer
Katie Southward et al., Leeds Institute of Molecular Medicine, UK

The histone deacetylase inhibitor vorinostat (SAHA) down-regulates c-FLIP and sensitises human non-small cell lung carcinoma cell lines to ionising radiation
Kylie McLaughlin et al., Queen’s University Belfast, UK

Colorectal tumour microRNAs – novel biomarkers of tumour progression and treatment response?
Edward Amankwatia et al., University of Dundee, UK

Identification of 14-3-3 as a novel regulator of the Wnt/ß-Catenin signalling pathway
Shiri Dovrat et al.,Tel Aviv University, Israel

Phenotypic heterogeneity in small cell lung cancer cells
Suzanne Meredith et al., University of Manchester, UK

Royal College of Radiologists Ross Prize Entrants

The Royal College of Radiologists (RCR) Ross Prizes are presented to clinical oncologists in training or recently appointed consultants adjudged to have presented the best proffered papers and best posters at the NCRI Cancer Conference.

Best proffered paper session presentation:

Optimisation and individualisation of heart-sparing breast radiotherapy techniques (The HeartSpare Study)
Frederick Bartlett, The Royal Marsden NHS Foundation Trust, London, UK & The Institute of Cancer Research, London, UK

Best poster:

A dose-response relationship for the incidence of radiation-related heart disease
Carolyn Taylor, University of Oxford, UK